Lallemand Pharma

Clinical Research

Lallemand Pharma has recently sponsored a multicentre, double-blind, randomized, clinical study involving two hundred eighty eight patients with moderate to very severe COPD : the Advanced Immunological Approach against COPD exacerbations, or AIACE study. This study showed benefits of PMBL® sublingual tablets as add-on therapy by significantly reducing the number of days of hospitalization for COPD patients.

Even though the primary end-point: reduction by 25% of the number of exacerbations was not significant, interesting secondary end-points were positive: reduction of the number of days with fever, reduction of the number of days in poor health, reduction of the number of days of hospitalization.

If you want to read more: AIACE results abstract